A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. Export

@article{citeulike:3130748, abstract = {Ten patients with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) were treated in an uncontrolled preliminary trial by oral administration of viable Lactobacillus casei strain Shirota (LcS) containing fermented milk. HTLV-1 provirus load, motor function, neurological findings, and immunological parameters were evaluated after 4 weeks. Although LcS did not change the frequencies or absolute numbers of all the examined cell surface phenotypes of peripheral blood mononuclear cells, NK cell activity was significantly increased after 4 weeks of oral administration of LcS preparation. Improvements in spasticity (modified Ashworth Scale scores) and urinary symptoms were also seen after LcS treatment. No adverse effect was observed in all the 10 patients throughout the study period. Our results indicated that LcS may be a safe and beneficial agent for the treatment of HAM/TSP; therefore randomized controlled studies are warranted.}, address = {Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.}, author = {Matsuzaki, T. and Saito, M. and Usuku, K. and Nose, H. and Izumo, S. and Arimura, K. and Osame, M.}, citeulike-article-id = {3130748}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.jns.2005.05.011}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/15961107}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=15961107}, day = {15}, doi = {10.1016/j.jns.2005.05.011}, issn = {0022-510X}, journal = {Journal of the neurological sciences}, keywords = {hamtsp, hamtsp\_therapy, probiotics, translational\_hamtsp}, month = {October}, number = {1-2}, pages = {75--81}, posted-at = {2008-08-18 04:00:43}, priority = {2}, title = {A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis.}, url = {http://dx.doi.org/10.1016/j.jns.2005.05.011}, volume = {237}, year = {2005} }

TY - JOUR ID - citeulike:3130748 L3 - citeulike-article-id:3130748 N2 - Ten patients with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) were treated in an uncontrolled preliminary trial by oral administration of viable Lactobacillus casei strain Shirota (LcS) containing fermented milk. HTLV-1 provirus load, motor function, neurological findings, and immunological parameters were evaluated after 4 weeks. Although LcS did not change the frequencies or absolute numbers of all the examined cell surface phenotypes of peripheral blood mononuclear cells, NK cell activity was significantly increased after 4 weeks of oral administration of LcS preparation. Improvements in spasticity (modified Ashworth Scale scores) and urinary symptoms were also seen after LcS treatment. No adverse effect was observed in all the 10 patients throughout the study period. Our results indicated that LcS may be a safe and beneficial agent for the treatment of HAM/TSP; therefore randomized controlled studies are warranted. IS - 1-2 JF - Journal of the neurological sciences SN - 0022-510X AD - Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. EP - 81 TI - A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. VL - 237 SP - 75 KW - hamtsp KW - hamtsp_therapy KW - probiotics KW - translational_hamtsp AU - Matsuzaki, T AU - Saito, M AU - Usuku, K AU - Nose, H AU - Izumo, S AU - Arimura, K AU - Osame, M PY - 2005/10/15/ UR - http://dx.doi.org/10.1016/j.jns.2005.05.011 ER -